Page last updated: 2024-09-05

dofequidar and technetium tc 99m sestamibi

dofequidar has been researched along with technetium tc 99m sestamibi in 2 studies

Compound Research Comparison

Studies (dofequidar)	Trials (dofequidar)	Recent Studies (post-2010) (dofequidar)	Studies (technetium tc 99m sestamibi)	Trials (technetium tc 99m sestamibi)	Recent Studies (post-2010) (technetium tc 99m sestamibi)
40	2	5	5,774	627	1,208

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Nishimura, T; Tatsumi, M; Tsuruo, T	1
Hu, Y; Mizoi, K; Naitoh, Y; Sasajima, T; Satoh, T; Shimada, N; Takahashi, M	1

Other Studies

2 other study(ies) available for dofequidar and technetium tc 99m sestamibi

Article	Year
Evaluation of MS-209, a novel multidrug-resistance-reversing agent, in tumour-bearing mice by technetium-99m-MIBI imaging. European journal of nuclear medicine and molecular imaging, 2002, Volume: 29, Issue:3 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Squamous Cell; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gene Expression; Genes, MDR; Humans; KB Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Quinolines; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Technetium Tc 99m Sestamibi; Tissue Distribution	2002
(99m)Tc-MIBI imaging for prediction of therapeutic effects of second-generation MDR1 inhibitors in malignant brain tumors. International journal of cancer, 2007, Dec-15, Volume: 121, Issue:12 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Autoradiography; Brain Neoplasms; Carcinoma 256, Walker; Cell Line, Tumor; Cell Proliferation; Cyclosporine; Cyclosporins; Cytotoxins; Drug Resistance, Neoplasm; Drug Synergism; Predictive Value of Tests; Quinolines; Radiopharmaceuticals; Rats; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Technetium Tc 99m Sestamibi; Tomography, Emission-Computed, Single-Photon; Vincristine	2007

Article

Year

Evaluation of MS-209, a novel multidrug-resistance-reversing agent, in tumour-bearing mice by technetium-99m-MIBI imaging.

European journal of nuclear medicine and molecular imaging, 2002, Volume: 29, Issue:3

Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Squamous Cell; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gene Expression; Genes, MDR; Humans; KB Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Quinolines; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Technetium Tc 99m Sestamibi; Tissue Distribution

2002

(99m)Tc-MIBI imaging for prediction of therapeutic effects of second-generation MDR1 inhibitors in malignant brain tumors.

International journal of cancer, 2007, Dec-15, Volume: 121, Issue:12

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Autoradiography; Brain Neoplasms; Carcinoma 256, Walker; Cell Line, Tumor; Cell Proliferation; Cyclosporine; Cyclosporins; Cytotoxins; Drug Resistance, Neoplasm; Drug Synergism; Predictive Value of Tests; Quinolines; Radiopharmaceuticals; Rats; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Technetium Tc 99m Sestamibi; Tomography, Emission-Computed, Single-Photon; Vincristine

2007